Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra M Poos

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Molecular Oncology|November 19, 2019
Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancerDoris Höflmayer, Amélie Steinhoff, Claudia Hube-Magg, et al.
Molecular Systems Biology|May 24, 2019
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networksJan-Philipp Mallm, Murat Iskar, Naveed Ishaque, et al.
Cancers|March 10, 2022
PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic PowerAlexandra M Poos, Cornelia Schroeder, Neeraja Jaishankar, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Molecular Oncology|November 19, 2019
Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancerDoris Höflmayer, Amélie Steinhoff, Claudia Hube-Magg, et al.
Molecular Systems Biology|May 24, 2019
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networksJan-Philipp Mallm, Murat Iskar, Naveed Ishaque, et al.
Cancers|March 10, 2022
PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic PowerAlexandra M Poos, Cornelia Schroeder, Neeraja Jaishankar, et al.
Blood|June 30, 2023
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysisAlexandra M Poos, Nina Prokoph, Moritz J Przybilla, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Pageof 3